Inflammatory Breast Cancer Stem Cells: Contributors to Aggressiveness, Metastatic Spread and Dormancy

Golen, Cynthia M. van; Golen, Kenneth L. van

doi:10.4172/2155-9929.s8-002

Cited by 3 publications

(3 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, 74% of human IBC samples contain a genetic signature compatible with a high composition of a high cancer stem cell composition. This is significantly higher than the 44% of non-IBC cells that yielded a similar result 66 .…”

Section: Research and Progressmentioning

confidence: 63%

“…Recent research has focused on the origins of IBC. A major step in this direction has been the finding of evidence that supports cancer stem cells playing a role in the robustness of IBC 66,67 . Tumor cells isolated from the SUM149 and MARY-X models of human IBC have been found to express both embryonal markers (Nestin, Rexl, and Stellar) and the classic breast cancer signature (CD44+/CD24-/CD133+/ aldehyde dehydrogenase-1 (ALDH1)+ 68 .…”

Section: Research and Progressmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory Breast Cancer: A Panoramic Overview

Golen¹

2018

J Rare Dis Res Treat

View full text Add to dashboard Cite

Inflammatory breast cancer (IBC) is a unique breast cancer with a highly virulent course and low 5-and 10-year survival rates. Although IBC only accounts for 1-5% of breast cancers it is estimated to account for 10% of breast cancer deaths annually in the United States. The accuracy of diagnosis and classification of this unique cancer is a major concern within the medical community. Multimodality treatment includes preoperative chemotherapy, mastectomy, and radiation therapy is the therapeutic mainstay and has been shown to improve prognosis. The potential for inaccurate diagnosis and misclassification in cases of IBC is increased by many factors. This includes the misleading initial symptoms of IBC. The early signs of IBC will present in women who have inflammation of the skin of the affected breast, as well as red or purple coloration of the inflamed area. Molecular studies have shown unique signature genes that are hallmarks of IBC. The current article reviews multiple aspects of primary inflammatory breast cancer.

show abstract

Section: Research and Progressmentioning

confidence: 63%

Section: Research and Progressmentioning

confidence: 99%

Inflammatory Breast Cancer: A Panoramic Overview

Golen¹

2018

J Rare Dis Res Treat

View full text Add to dashboard Cite

show abstract

“…The effect of crenolanib treatment on tumor recurrences needs to be assessed. Most recurrences occur due to the outgrowth of tumor-initiating cells, and IBC has a very high proportion of tumor-initiating cells [46] , [47] , [48] .…”

Section: Discussionmentioning

confidence: 99%

Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)

et al. 2017

View full text Add to dashboard Cite

PURPOSE: Inflammatory breast cancer (IBC) is arguably the deadliest form of breast cancer due to its rapid onset and highly invasive nature. IBC carries 5- and 10-year disease-free survival rates of ~45% and <20%, respectively. Multiple studies demonstrate that in comparison with conventional breast cancer, IBC has a unique molecular identity. Here, we have identified platelet-derived growth factor receptor alpha (PDGFRA) as being uniquely expressed and active in IBC patient tumor cells. EXPERIMENTAL DESIGN: Here we focus on characterizing and targeting PDGFRA in IBC. Using gene expression, we analyzed IBC patient samples and compared them with non-IBC patient samples. Further, using IBC cells in culture, we determined the effect of small molecules inhibitors in both in vitro and in vivo assays. RESULTS: In IBC patients, we show more frequent PDGFRA activation signature than non-IBC samples. In addition, the PDGFRA activation signature is associated with shorter metastasis-free survival in both uni- and multivariate analyses. We also demonstrate that IBC cells express active PDGFRA. Finally, we show that PDGFRA targeting by crenolanib (CP-868-596), but not imatinib (STI571), two small molecule inhibitors, interferes with IBC cell growth and emboli formation in vitro and tumor growth in vivo. CONCLUSIONS: Our data suggest that PDGFRA may be a promising target for therapy in IBC.

show abstract

Management of locally advanced breast cancer—perspectives and future directions

et al. 2015

View full text Add to dashboard Cite

Locally advanced breast cancer (LABC) constitutes a heterogeneous entity that includes advanced-stage primary tumours, cancers with extensive nodal involvement and inflammatory breast carcinomas. Although the definition of LABC can be broadened to include some large operable breast tumours, we use this term to strictly refer to inoperable cancers that are included in the above-mentioned categories. The prognosis of such tumours is often unfavourable; despite aggressive treatment, many patients eventually develop distant metastases and die from the disease. Advances in systemic therapy, including radiation treatment, surgical techniques and the development of new targeted agents have significantly improved clinical outcomes for patients with this disease. Notwithstanding these advances, LABC remains an important clinical problem, particularly in developing countries and those without widely adapted breast cancer awareness programmes. The optimal management of LABC requires a multidisciplinary approach, a well-coordinated treatment schedule and close cooperation between medical, surgical and radiation oncologists. In this Review, we discuss the current state of the art and possible future treatment strategies for patients with LABC.

show abstract

Inflammatory Breast Cancer Stem Cells: Contributors to Aggressiveness, Metastatic Spread and Dormancy

Cited by 3 publications

References 64 publications

Inflammatory Breast Cancer: A Panoramic Overview

Inflammatory Breast Cancer: A Panoramic Overview

Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)

Management of locally advanced breast cancer—perspectives and future directions

Contact Info

Product

Resources

About